GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Net Change in Cash

Zhaoke Ophthalmology (HKSE:06622) Net Change in Cash : HK$-365.40 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Zhaoke Ophthalmology's Net Change in Cash for the six months ended in Dec. 2024 was HK$-155.81 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-365.40 Mil.

Zhaoke Ophthalmology Net Change in Cash Historical Data

The historical data trend for Zhaoke Ophthalmology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology Net Change in Cash Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial -106.30 2,526.48 -460.17 -278.62 -363.67

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 164.16 -45.53 -233.09 -209.58 -155.81

Zhaoke Ophthalmology Net Change in Cash Calculation

Zhaoke Ophthalmology's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-270.893+-124.328+-12.942+44.495
=-363.67

Zhaoke Ophthalmology's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-103.895+-39.516+-22.779+10.378
=-155.81

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-365.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Net Change in Cash
Comparable Companies
HKSE:02496 HKSE:01244 HKSE:02511 HKSE:06998 HKSE:02898 HKSE:02126 HKSE:02185 HKSE:06628 HKSE:09939 HKSE:02137 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
9FX:Germany
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Website
https://www.zkoph.com
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology Headlines

No Headlines